Last updated: April 23, 2026
What is BRYHALI and what is its clinical development status?
BRYHALI is the trade name for brensocatib, a drug developed by Insmed for non-cystic fibrosis bronchiectasis (NCFB) characterized by recurrent exacerbations. The program is built around inhibition of dipeptidyl peptidase-1 (DPP1), aiming to reduce neutrophil elastase activity via upstream modulation of serine protease activation pathways.
Core clinical program (key readouts)
Brensocatib’s Phase 2 and Phase 3 development is anchored by the PULSE program (Phase 2) and the recurrent exacerbation Phase 3 trials (including DREAM). The most commercially relevant endpoint is time to first exacerbation and annualized rate of exacerbations versus placebo.
Regulatory-positioning endpoint
Commercial uptake depends primarily on whether data demonstrate:
- Reduction in annualized exacerbation rate
- Delayed onset via time-to-first exacerbation
- Consistent benefit across the intended label population (exacerbator phenotype)
What is the latest clinical trials update?
Clinical development updates for brensocatib are typically trackable through:
- ClinicalTrials.gov study status changes (recruitment, results posted, changes to protocol)
- Regulatory filings and label expansions by major geographies
- Press releases and investor materials reporting interim or final results
No complete, current, trial-by-trial update set can be produced from the information available in this chat. This prevents an accurate, source-cited tabulation of “latest” trial status, dates, and outcomes across geographies.
What is the competitive market context for non-CF bronchiectasis?
Disease and market drivers
Non-cystic fibrosis bronchiectasis is characterized by chronic airway inflammation, infection risk, and exacerbations. The market is driven by:
- High exacerbation burden and antibiotic use
- Need for long-term disease-modifying and exacerbation-reducing therapies
- Underdiagnosis and expanding awareness driving treatment initiation
Key competitive classes
Brensocatib competes in a setting that includes:
- Macrolides (immunomodulatory/antibacterial use to reduce exacerbations)
- Inhaled therapies (mucociliary clearance and anti-inflammatory approaches)
- Systemic anti-inflammatory strategies in select pipelines
- Supportive regimens tied to microbiology and exacerbation prevention
For investment and forecasting, the central competitive question is whether brensocatib is positioned as a first-line disease-modifying option for frequent exacerbators versus a later-line add-on to existing regimens.
How big is the addressable market and where does BRYHALI fit?
Because pricing and label inclusion criteria govern capture, a credible projection requires at least:
- Current label population size (diagnosed NCFB, exacerbator prevalence)
- Uptake assumptions by line of therapy and geography
- Pricing inputs by market (WAC and discounting context)
- Adherence and persistence (dose frequency and tolerability)
Those inputs are not available in this chat in a way that permits a complete, accurate, source-cited projection.
What revenue projection can be made for BRYHALI?
A defensible revenue model needs:
- Launch/first-commercial-year basis
- Forecast of eligible patient numbers
- Expected penetration rates and time-to-peak
- Drug pricing assumptions and reimbursement dynamics
No citable label launch year, pricing terms, or geography-specific commercialization timing is present here, so a complete revenue projection cannot be produced without fabricating inputs.
Key Takeaways
- BRYHALI (brensocatib) is a DPP1 inhibitor targeting exacerbation reduction in non-cystic fibrosis bronchiectasis.
- The program’s commercial logic centers on annualized exacerbation reduction and time-to-first exacerbation.
- A current “clinical trials update,” quantified competitor and label-specific market sizing, and a fully sourced revenue projection cannot be generated from the provided information in this chat.
FAQs
-
What is BRYHALI’s mechanism of action?
Brensocatib inhibits dipeptidyl peptidase-1 (DPP1) to reduce activation of downstream serine proteases implicated in neutrophilic inflammation.
-
What clinical endpoints matter most for BRYHALI’s market uptake?
The principal endpoints are annualized exacerbation rate and time to first exacerbation in the target exacerbator population.
-
Who are BRYHALI’s main competitive comparators in NCFB?
Common comparators include macrolide-based strategies and inhaled supportive anti-inflammatory or mucociliary regimens, with pipeline therapies varying by region and indication.
-
Does brensocatib target infection directly or inflammation upstream?
It is positioned as a disease-modifying anti-inflammatory upstream strategy rather than an antibacterial.
-
Can a revenue forecast be produced without label, pricing, and uptake inputs?
A credible forecast requires label inclusion, pricing, and uptake assumptions that are not provided here.
References
[1] ClinicalTrials.gov. “Brensocatib” (search results and trial records). https://clinicaltrials.gov/
[2] FDA. Drug approval and label database (if applicable for BRYHALI/brensocatib). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] EMA. Medicines (if applicable for brensocatib). https://www.ema.europa.eu/
[4] Insmed. Investor presentations and press releases for brensocatib program updates. https://www.insmed.com/
